The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical ‘cure’
Top Cited Papers
- 1 March 2005
- journal article
- Published by Oxford University Press (OUP) in Acta Endocrinologica
- Vol. 152 (3) , 379-387
- https://doi.org/10.1530/eje.1.01863
Abstract
Background and aim: The aim of this study was to illustrate the present role of transsphenoidal surgery as primary therapy in GH-secreting adenomas, and to compare the results concerning control of disease with previous series using older criteria of cure. Method: We report on a consecutive series of 688 acromegalic patients treated over a time period of 19 years. Biochemical cure was defined as normalisation of basal GH level, suppression of GH levels to below 1 ng/ml during an oral glucose load and normalisation of IGF-I levels. Of the 506 patients undergoing primary transsphenoidal surgery, a total of 57.3% postoperatively fulfilled the criteria used. Results: The rate of biochemical ‘cure’ correlated with the magnitude of the initial GH levels, the tumour size and invasion. The overall complication rate was below 2%. Mortality in this series was 0.1% (1 of 688). During a follow-up period of 10.7 years only two recurrences (0.4%) occurred. However, in the patients treated by transcranial surgery and by repeat surgery the cure rate was found to be relatively low (5.2 and 21.3% respectively). Conclusions: These data suggest that surgery remains with very few exceptions the primary treatment of acromegaly for (i) a high cure rate, (ii) low morbidity, (iii) low recurrence rate and (iv) immediate decline of GH. Based on current criteria of cure, recurrences are uncommon. However, cure by surgery alone is improbable in patients harbouring extended, invasive tumours with high secretory activity, in whom further adjuvant treatment is mandatory.Keywords
This publication has 36 references indexed in Scilit:
- Long‐term outcome and mortality after transsphenoidal adenomectomy for acromegalyClinical Endocrinology, 2003
- Primary Medical Therapy for Acromegaly: An Open, Prospective, Multicenter Study of the Effects of Subcutaneous and Intramuscular Slow-Release Octreotide on Growth Hormone, Insulin-Like Growth Factor-I, and Tumor SizeJournal of Clinical Endocrinology & Metabolism, 2002
- Guidelines for Acromegaly ManagementJournal of Clinical Endocrinology & Metabolism, 2002
- Long-Term Safety and Efficacy of Depot Long-Acting Somatostatin Analogs for the Treatment of AcromegalyJournal of Clinical Endocrinology & Metabolism, 2002
- Treatment of Acromegaly with the Growth Hormone–Receptor Antagonist PegvisomantNew England Journal of Medicine, 2000
- MEDICAL THERAPY FOR ACROMEGALYEndocrinology and Metabolism Clinics of North America, 1999
- Long-Term Mortality after Transsphenoidal Surgery and Adjunctive Therapy for AcromegalyJournal of Clinical Endocrinology & Metabolism, 1998
- Mortality and Cancer Incidence in Acromegaly: A Retrospective Cohort StudyJournal of Clinical Endocrinology & Metabolism, 1998
- Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients--a clinical research center study [published erratum appears in J Clin Endocrinol Metab 1995 Nov;80(11):3238]Journal of Clinical Endocrinology & Metabolism, 1995
- Determinants of clinical outcome and survival in acromegalyClinical Endocrinology, 1994